Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin Dose Range Study in NSCLC Cachexia
NCT00622193Phase 2Completed
- Start
- Mar 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of anamorelin in cancer cachexia (3 arms). Primary endpoints: Hand grip strength at 12 weeks and Body weight at 12 weeks. Started Mar 2008; status: completed.
02
Drugs
anamorelin
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT00622193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622193.